Publicly traded biotechnology company Agenus Inc. has appointed Shalini Sharp to its board of directors. Sharp has served as vice president and chief financial officer of the company since 2006. She will take her post on the company's board in May and will step down from her role as chief financial officer.
"I am delighted that Agenus is now in its strongest financial position in recent history, and I look forward to working with the Agenus team in my new capacity," said Sharp.
"Shalini has spearheaded numerous financing and business development transactions that have been critical to the success of Agenus, most recently our expanded agreement with GlaxoSmithKline," said Garo H. Armen, chairman and CEO of Agenus. "Her strategic insight and record of execution will continue to be an outstanding asset to Agenus."
Agenus, which is based in Lexington, Mass., is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products.
Sharp joined Agenus in 2003 and has served in increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development activities. Prior to Agenus, she held similar roles at Elan Pharmaceuticals between 1998 and 2003, including serving as chief of staff to the chairman of the board of directors during its restructuring period.
Sharp has a bachelor's degree and master's degree in business administration from Harvard University.